Authors

Vassiliki Papadimitrakopoulou, MD, MD Anderson Cancer Center

Latest:

Dr. Giri on Genes that Carry a Risk for Prostate Cancer

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

Veda N. Giri, MD

Latest:

Dr. Giri on the PROGRESS Registry for Genetic Testing in Prostate Cancer

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Vernon K. Sondak, MD

Latest:

Dr. Sondak on Ipilimumab in Melanoma

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

Vernon K. Sondak, MD, Moffitt Cancer Center

Veronique Dieras, MD

Latest:

Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

Veronique Leblond, MD

Latest:

Dr. Leblond Discusses Treatment After Relapse in CLL

Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.

Vicki Albrecht, PhD

Latest:

Build Referrals and Strengthen Revenues

Multiple resources are available to help community oncologists maintain success by increasing awareness of their practice, providing the most innovative treatments to their patients, and preparing for the future of oncology care.

Vicki Hyman

Latest:

Esserman Helps Push Breast Cancer Prevention Beyond Routine Screenings

Laura J. Esserman, MD, MBA, a 2018 Giants of Cancer Care® award winner in the Cancer Diagnostics category led the way in designing the I-SPY clinical trials, a groundbreaking effort to match patients with breast cancer to potential therapies based on molecular drivers of disease. She also has advocated for a greater understanding of the biological drivers of breast cancer, rather than relying on mass screening programs, to better analyze early disease.

Vicki Keedy, MD

Latest:

Dr. Keedy Discusses Imaging Biomarkers in Osteosarcoma

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses a trial looking at quantitative imaging biomarkers of treatment response in osteosarcoma.

Vicky Makker, MD

Latest:

Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the Future

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.

Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

Latest:

The Future of Endometrial Cancer Treatment

Experts give insight on what they are looking forward to in the endometrial cancer space.

Victor Villalobos, MD, PhD, University of Colorado

Victor Villalobos, MD, PhD, University of Colorado Denver

Victor Villalobos, MD, PhD, University of Colorado School of Medicine

Victor Y. Yazbeck, MD

Latest:

Dr. Yazbeck on Idelalisib Plus BR in Relapsed/Refractory CLL

Victor Y. Yazbeck, MD, assistant professor, Hematology-Oncology, Internal Medicine, Virginia Commonwealth University (VCU) School of Medicine, VCU Massey Cancer Center, discusses a phase III study examining idelalisib plus bendamustine rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.

Victoria Atkinson, MD

Latest:

Dr. Atkinson Discusses BRAF-Mutant Metastatic Melanoma

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

Victoria M. Villaflor, MD

Latest:

Clinical Scenario: Metastatic EBV-Positive NPC

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Victoria Villaflor, MD

Latest:

Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.

Vidhya Karivedu, MD

Latest:

Metformin Plus Chemoradiation Induces Antitumorigenic Immune Response in HNSCC

Vidhya Karivedu, MD, fellow/resident at the University of Cincinnati College of Medicine, discusses the antitumorigenic immune response seen with the combination of metformin and chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.